Selenium, Lead, and Cadmium Levels in Renal Failure Patients in China

Chen, Bing; Lamberts, Ludwig V.; Behets, Geert J.; Zhao, Tingting; Zhou, Mingxiang; Liu, Gang; Hou, Xianghua; Guan, Guangju; D’Haese, Patrick C.

doi:10.1007/s12011-009-8340-y

Cited by 36 publications

(24 citation statements)

References 28 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, mean serum selenium levels were significantly lower in HPs than in healthy controls (Table 1) as also reported by others [5][6][7][23][24][25][26][27]. In contrast, a study of the influence of glucose in the dialysate on oxidative stress intensity, glutathione activity, and plasma Se in HPs [5] found plasma Se concentrations to be increased by hemodialysis.…”

Section: Resultssupporting

confidence: 87%

Altered Serum Selenium and Uric Acid Levels and Dyslipidemia in Hemodialysis Patients Could be Associated with Enhanced Cardiovascular Risk

Moral

Agil

Navarro-Alarcón

et al. 2011

Biol Trace Elem Res

View full text Add to dashboard Cite

In the present study, the first objective was to follow up serum selenium (Se) concentrations in 117 hemodialysis patients (HPs) during a 2-year longitudinal study, relating concentrations to biochemical indexes (n = 6; namely lipoprotein profile, uric acid, and total protein levels). It was also evaluated whether the disease is associated with an enhanced cardiovascular risk. A healthy control group (n = 50) was also studied. Mean serum Se levels were significantly lower in HPs than in the controls (p = 0.002); mean levels significantly increased from the first to third blood sampling (p < 0.001). HPs showed a marked dyslipidemia, with a significant reduction in total cholesterol, low-density lipoprotein, and high-density lipoprotein cholesterol levels and a significant increase in triglyceride levels (p < 0.001). HPs showed a marked hyperuricemia (p < 0.001). Serum selenium levels in HPs were correlated negatively with uric acid levels (inflammation biomarker; p < 0.01). In HPs, serum Se levels are reduced due to their disease (chronic renal failure). Serum Se levels rose until the third blood sampling. The marked dyslipidemia and hyperuricemia found in HPs and the negative correlation between the serum Se and uric acid levels in these patients could imply an enhanced cardiovascular risk.

show abstract

Section: Resultssupporting

confidence: 87%

Altered Serum Selenium and Uric Acid Levels and Dyslipidemia in Hemodialysis Patients Could be Associated with Enhanced Cardiovascular Risk

Moral

Agil

Navarro-Alarcón

et al. 2011

Biol Trace Elem Res

View full text Add to dashboard Cite

show abstract

“…Thus, Bing Chen et al, found a positive correlation between the blood cadmium levels and the time on dialysis. Such observations were also been reported by Skarupskiene et al, [33,34]. Sharupskiene et al had also reported elevated blood cadmium levels in haemodialysis patients [34].…”

Section: Resultssupporting

confidence: 80%

“…D Van Renterghem et al, had demonstrated elevated concentrations of cadmium in the sera of five patients who were on haemodiafiltration [31]. Bing Chen et al, who studied the whole blood and serum samples of stable Chinese chronic renal failure patients (n=81), haemodialysis patients (n=135), posttransplant patients (n=60) and subjects with normal renal functions (n=42), found a high prevalence of elevated cadmium levels in the haemodialysis patients [33]. The blood cadmium level in the haemodialysis patients was also significantly higher as compared to that in the subjects with stable chronic renal failure (p<0.01).…”

Section: Resultsmentioning

confidence: 99%

Blood Arsenic and Cadmium Concentrations in End-Stage Renal Disease Patients who were on Maintenance Haemodialysis

Palaneeswari

Pm²,

Silambanan³

et al. 2013

JCDR

View full text Add to dashboard Cite

Background: In India, there is a rising burden of chronic diseases like hypertension and diabetes. It has been estimated that 25-40% of these patients are likely to develop chronic kidney disease (CKD), with a significant percentage requiring renal replacement therapy. Haemodialysis is the most common method which is used to treat advanced and permanent kidney failure. Derangements in the metabolism of several toxic and trace elements such as antimony, arsenic cadmium, molybdenum, nickel, and selenium have been reported for several decades in patients with chronically reduced renal functions. Overall, the available literature suggests that the blood levels of some elements such as cadmium, chromium, fluorine, iodine, lead, or vanadium are high in end-stage renal disease (ESRD). Aim and Objectives:Our aim was to study the levels of blood arsenic and cadmium in ESRD patients who were on maintenance haemodialysis (MHD), and to study whether there was any relationship between their concentrations and the duration of the MHD. Methods:The blood lead levels were determined in 50 healthy subjects with normal renal functions and in 50 patients with ESRD, who were on MHD. None of them had any history of smoking or any industrial exposure. Results:The results of the study revealed that the blood arsenic and cadmium concentrations were higher in the ESRD patients who were on MHD than in the healthy adults. The blood arsenic and cadmium concentrations were found to increase with the duration of the MHD. Conclusion:The mild increase in the blood arsenic and cadmium concentrations, with an increase in the duration of the MHD in the study population, may be viewed in the wider context, that a prolonged exposure to arsenic and cadmium, even at low levels, may result in renal damage and/or progression of an already existing CKD.

show abstract

“…Bing Chen et al, who studied the whole blood and the serum samples of Chinese stable chronic renal failure patients, haemodialysis patients, post-transplant patients and subjects with normal renal functions, found a low prevalence of the elevated lead levels (>200 µg/L) in the dialysis patients, which was similar to the findings of Su-Hui Lee et al, [9,10]. Ja-Liang Lin et al, studied the blood lead levels in 315 patients who were on chronic peritoneal dialysis in an 18-month prospective study.…”

Section: Discussionsupporting

confidence: 58%

Blood Lead in End-Stage Renal Disease (ESRD) Patients who were on Maintainence Haemodialysis

Rajan²,

Silambanan³

et al. 2012

JCDR

View full text Add to dashboard Cite

Background: In India, there is rising burden of chronic diseases like hypertension and diabetes. It has been estimated that 25-40% of these patients are likely to develop CKD, with a significant percentage requiring renal replacement therapy. Haemodialysis is the most common method which is used to treat advanced and permanent kidney failure. The derangements in the metabolism of several toxic and trace elements such as antimony, arsenic, cadmium, molybdenum, nickel, and selenium have been reported for several decades in patients with chronically reduced renal function. Overall, the available literature suggests that the blood levels of some elements such as cadmium, chromium, fluorine, iodine, lead and vanadium are high in ESRD. Aim and Objectives:Our aim was to study the levels of blood lead in the End-Stage Renal Disease (ESRD) patients who were on Maintenance Haemodialysis (MHD), and to study whether there was any relationship between the blood lead concentration and the duration of MHD. Methods:The blood lead level was determined in 50 healthy subjects with normal renal function and in 50 patients with ESRD who were on MHD. None of them had a history of smoking or any industrial exposure. Results:The results of this study revealed that the blood lead level was higher in the ESRD patients who were on MHD than in the healthy adults. The blood lead concentration was found to increase with the duration of the MHD.

show abstract

Selenium, Lead, and Cadmium Levels in Renal Failure Patients in China

Cited by 36 publications

References 28 publications

Altered Serum Selenium and Uric Acid Levels and Dyslipidemia in Hemodialysis Patients Could be Associated with Enhanced Cardiovascular Risk

Altered Serum Selenium and Uric Acid Levels and Dyslipidemia in Hemodialysis Patients Could be Associated with Enhanced Cardiovascular Risk

Blood Arsenic and Cadmium Concentrations in End-Stage Renal Disease Patients who were on Maintenance Haemodialysis

Blood Lead in End-Stage Renal Disease (ESRD) Patients who were on Maintainence Haemodialysis

Contact Info

Product

Resources

About